Association of nonalcoholic fatty liver disease and liver cancer

World Journal of Gastroenterology

Volumn 21, Issue 3, 2015, Pages 913-918

  Schulz, Perla Oliveira ^a   Ferreira, Fabio Gonçalves ^a   De Fátima Araújo Nascimento, Maria ^a   Vieira, Andrea ^a   Ribeiro, Mauricio Alves ^a   David, André Ibrahim ^b   Szutan, Luiz Arnaldo ^a  

^a Interdisciplinary Center for Clinical Neuromodulation   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Colorectal liver metastases; Hepatocellular carcinoma; Intrahepatic cholangiocarcinoma; Liver fibrosis; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Indexed keywords

ALCOHOL ABUSE; ARTICLE; AUTOIMMUNE HEPATITIS; BILE DUCT CARCINOMA; BODY MASS; COLORECTAL CANCER; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS C; HEPATOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; LIVER CANCER; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER METASTASIS; MAJOR CLINICAL STUDY; MEDICAL HISTORY; NONALCOHOLIC FATTY LIVER; RETROSPECTIVE STUDY; RISK FACTOR; STEATOSIS; WILSON DISEASE; AGED; BILE DUCT NEOPLASMS; BRAZIL; CANCER GRADING; CARCINOMA, HEPATOCELLULAR; CHI SQUARE DISTRIBUTION; CHOLANGIOCARCINOMA; COLORECTAL NEOPLASMS; FEMALE; INTRAHEPATIC BILE DUCT; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER RESECTION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; ODDS RATIO; PATHOLOGY; PREVALENCE; RISK ASSESSMENT; SECONDARY; TERTIARY CARE CENTER;

AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BRAZIL; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; CHOLANGIOCARCINOMA; COLORECTAL NEOPLASMS; FEMALE; HEPATECTOMY; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM GRADING; NON-ALCOHOLIC FATTY LIVER DISEASE; ODDS RATIO; PREVALENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TERTIARY CARE CENTERS;

EID: 84921471030     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i3.913     Document Type: Article

References (43)

1. Marchesini G, Babini M. Nonalcoholic fatty liver disease and the metabolic syndrome. Minerva Cardioangiol 2006; 54: 229-239 [PMID: 16778754].
2. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285 [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x].
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107].
4. van der Bilt JD, Kranenburg O, Borren A, van Hillegersberg R, Borel Rinkes IH. Ageing and hepatic steatosis exacerbate ischemia/reperfusion-accelerated outgrowth of colorectal micrometastases. Ann Surg Oncol 2008; 15: 1392-1398 [PMID: 18335279 DOI: 10.1245/s10434-007-9758-0].
5. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576 [PMID: 17570226 DOI: 10.1053/j.gastro.2007.04.061].
6. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005; 366: 1303-1314 [PMID: 16214602 DOI: 10.1016/S0140-6736(05)67530-7].
7. Michelini E, Lonardo A, Ballestri S, Costantini M, Caporali C, Bonati ME, Bertolotti M, Iori R, Loria P. Is cholangiocarcinoma another complication of insulin resistance: A report of three cases. Metab Syndr Relat Disord 2007; 5: 194-202 [PMID: 18370827 DOI: 10.1089/met.2006.0018].
8. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace. J Hepatol 2012; 56: 1384-1391 [PMID: 22326465 DOI: 10.1016/j.jhep.2011.10.027].
9. Hill-Baskin AE, Markiewski MM, Buchner DA, Shao H, DeSantis D, Hsiao G, Subramaniam S, Berger NA, Croniger C, Lambris JD, Nadeau JH. Diet-induced hepatocellular carcinoma in genetically predisposed mice. Hum Mol Genet 2009; 18: 2975-2988 [PMID: 19454484 DOI: 10.1093/hmg/ddp236].
10. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004; 24: 115-125 [PMID: 15192785 DOI: 10.1055/s-2004-828889].
11. Reddy SK, Hyder O, Marsh JW, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, Pulitano C, Barroso E, Aldrighetti L, Geller DA, Sempoux C, Herlea V, Popescu I, Anders R, Rubbia-Brandt L, Gigot JF, Mentha G, Pawlik TM. Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma. J Gastrointest Surg 2013; 17: 748-755 [PMID: 23355033 DOI: 10.1007/s11605-013-2149-x].
12. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER-Medicare database. Hepatology 2011; 54: 463-471 [PMID: 21538440 DOI: 10.1002/hep.24397].
13. Wong VW, Wong GL, Tsang SW, Fan T, Chu WC, Woo J, Chan AW, Choi PC, Chim AM, Lau JY, Chan FK, Sung JJ, Chan HL. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut 2011; 60: 829-836 [PMID: 21339204 DOI: 10.1136/gut.2011.237974].
14. Shen Z, Ye Y, Bin L, Yin M, Yang X, Jiang K, Wang S. Metabolic syndrome is an important factor for the evolution of prognosis of colorectal cancer: Survival, recurrence, and liver metastasis. Am J Surg 2010; 200: 59-63 [PMID: 20074697 DOI: 10.1016/j.amjsurg.2009.05.005].
15. Cotrim HP, Parise ER, Oliveira CP, Leite N, Martinelli A, Galizzi J, Silva Rde C, Mattos A, Pereira L, Amorim W, Ivantes C, Souza F, Costa M, Maia L, Pessoa M, Oliveira F. Nonalcoholic fatty liver disease in Brazil. Clinical and histological profile. Ann Hepatol 2011; 10: 33-37 [PMID: 21301007].
16. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321 [PMID: 15915461 DOI: 10.1002/hep.20701].
17. deAlwis NM, Day CP. Non-alcoholic fatty liver disease: The mist gradually clears. J Hepatol 2008; 48 Suppl 1: S104-S112 [PMID: 18304679 DOI: 10.1016/j.jhep.2008.01.009].
18. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-1978 [PMID: 20209604 DOI: 10.1002/hep.23527].
19. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009; 24: 248-254 [PMID: 19032450 DOI: 10.1111/j.1440-1746.2008.05640.x].
20. Hamady ZZ, Rees M, Welsh FK, Toogood GJ, Prasad KR, John TK, Lodge JP. Fatty liver disease as a predictor of local recurrence following resection of colorectal liver metastases. Br J Surg 2013; 100: 820-826 [PMID: 23354994 DOI: 10.1002/bjs.9057].
21. Fingleton B. Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci 2006; 11: 479-491 [PMID: 16146745 DOI: 10.2741/1811].
22. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000; 14: 163-176 [PMID: 10652271].
23. Kharbanda KK, Rogers DD, Wyatt TA, Sorrell MF, Tuma DJ. Transforming growth factor-beta induces contraction of activated hepatic stellate cells. J Hepatol 2004; 41: 60-66 [PMID: 15246209 DOI: 10.1016/j.jhep.2004.03.019].
24. Gorden DL, Fingleton B, Crawford HC, Jansen DE, Lepage M, Matrisian LM. Resident stromal cell-derived MMP-9 promotes the growth of colorectal metastases in the liver microenvironment. Int J Cancer 2007; 121: 495-500 [PMID: 17417772 DOI: 10.1002/ijc.22594].
25. Hayashi S, Masuda H, Shigematsu M. Liver metastasis rare in colorectal cancer patients with fatty liver. Hepatogastroenterology 1997; 44: 1069-1075 [PMID: 9261601].
26. Tamura R, Masuda H, Ishii Y, Nemoto N. Relationship between fatty liver and liver metastasis in rats given injection of rat colon cancer cell line. Hepatogastroenterology 1999; 46: 167-171 [PMID: 10228783].
27. Karube H, Masuda H, Hayashi S, Ishii Y, Nemoto N. Fatty liver suppressed the angiogenesis in liver metastatic lesions. Hepatogastroenterology 2000; 47: 1541-1545 [PMID: 11148998].
28. Augustin G, Bruketa T, Korolija D, Milosevic M. Lower incidence of hepatic metastases of colorectal cancer in patients with chronic liver diseases: Meta-analysis. Hepatogastroenterology 2013; 60: 1164-1168 [PMID: 23803379 DOI: 10.5754/hge11561].
29. Murono K, Kitayama J, Tsuno NH, Nozawa H, Kawai K, Sunami E, Akahane M, Watanabe T. Hepatic steatosis is associated with lower incidence of liver metastasis from colorectal cancer. Int J Colorectal Dis 2013; 28: 1065-1072 [PMID: 23392476 DOI: 10.1007/s00384-013-1656-2].
30. VanSaun MN, Lee IK, Washington MK, Matrisian L, Gorden DL. High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model. Am J Pathol 2009; 175: 355-364 [PMID: 19541928 DOI: 10.2353/ajpath.2009.080703].
31. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-2072 [PMID: 16648507 DOI: 10.1200/JCO.2005.05.3074].
32. Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, Rougier P, Nordlinger B. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006; 243: 1-7 [PMID: 16371728 DOI: 10.1097/01.sla.0000193603.26265.c3].
33. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: A case-control study among United States Veterans. Am J Gastroenterol 2001; 96: 2462-2467 [PMID: 11513191 DOI: 10.1111/j.1572-0241.2001.04054.x].
34. Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002; 36: 150-155 [PMID: 12085359 DOI: 10.1053/jhep.2002.33713].
35. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638 [PMID: 12711737 DOI: 10.1056/NEJMoa021423].
36. Qian Y, Fan JG. Obesity, fatty liver and liver cancer. Hepatobiliary Pancreat Dis Int 2005; 4: 173-177 [PMID: 15908310].
37. Pischon T, Nöthlings U, Boeing H. Obesity and cancer. Proc Nutr Soc 2008; 67: 128-145 [PMID: 18412987 DOI: 10.1017/S0029665108006976].
38. Amarapurkar DN, Patel ND, Kamani PM. Impact of diabetes mellitus on outcome of HCC. Ann Hepatol 2008; 7: 148-151 [PMID: 18626433].
39. Fair AM, Montgomery K. Energy balance, physical activity, and cancer risk. Methods Mol Biol 2009; 472: 57-88 [PMID: 19107429 DOI: 10.1007/978-1-60327-492-0-3].
40. Schlienger JL, Luca F, Vinzio S, Pradignac A. [Obesity and cancer]. Rev Med Interne 2009; 30: 776-782 [PMID: 19524333 DOI: 10.1016/j.revmed.2009.04.007].
41. Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK, Canbay A. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011; 128: 2436-2443 [PMID: 21128245 DOI: 10.1002/ijc.25797].
42. Alexander J, Torbenson M, Wu TT, Yeh MM. Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: A clinical and pathological study. J Gastroenterol Hepatol 2013; 28: 848-854 [PMID: 23302015 DOI: 10.1111/jgh.12116].
43. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-241 [PMID: 20071471 DOI: 10.1001/jama.2009.2014].